Skip to NavigationSkip to content

Rixathon

UK launch of two Novartis biosimilars could cut NHS costs

Sandoz, a division of Swiss pharma giant Novartis, has revealed that two of its biosimilars – Rixathon (biosimilar rituximab) and Erelzi (biosimilar etanercept) – are now available in the UK for use in Europe. Both new medicines have been proven to be non-inferior to their reference products, MabThera and Enbrel, respectively.

Novartis receives European biosimilar approval for Roche blockbuster

Sandoz, a division within Novartis, has received European Commission approval for its biosimilar version of Roche’s Rituxan (also known as MabThera). Rituxan garnered Roche $7.5 billion in global sales last year and this latest approval adds another challenge to Roche core drug sales.

Rixathon, the name of Novartis’ biosimilar, comes after Celltrion’s approval for its Truxima in February and, with a further five biosimilar Rituxan applications going through the European commission, the drug looks set to face serious competition.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches